Furthermore, knockdown of SALL4 can restore cisplatin sensitivity in acquired resistant lung cancer cells via the AKT/mTOR signaling pathway [46], and the antineoplastic drug entinostat can target SALL4-positive lung cancer [133]. The gene discussed is AKT1; the disease is lung carcinoma.